[go: up one dir, main page]

HUP0301422A3 - Pharmaceutical compositions of estrogenic agents - Google Patents

Pharmaceutical compositions of estrogenic agents

Info

Publication number
HUP0301422A3
HUP0301422A3 HU0301422A HUP0301422A HUP0301422A3 HU P0301422 A3 HUP0301422 A3 HU P0301422A3 HU 0301422 A HU0301422 A HU 0301422A HU P0301422 A HUP0301422 A HU P0301422A HU P0301422 A3 HUP0301422 A3 HU P0301422A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
estrogenic agents
estrogenic
agents
pharmaceutical
Prior art date
Application number
HU0301422A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HUP0301422A2 publication Critical patent/HUP0301422A2/hu
Publication of HUP0301422A3 publication Critical patent/HUP0301422A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0301422A 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents HUP0301422A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21619200P 2000-07-06 2000-07-06
PCT/US2001/020993 WO2002003987A2 (en) 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents

Publications (2)

Publication Number Publication Date
HUP0301422A2 HUP0301422A2 (hu) 2003-09-29
HUP0301422A3 true HUP0301422A3 (en) 2006-07-28

Family

ID=22806095

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301422A HUP0301422A3 (en) 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents

Country Status (26)

Country Link
US (2) US20020031548A1 (hu)
EP (1) EP1309327B1 (hu)
JP (1) JP2004502733A (hu)
KR (2) KR100862174B1 (hu)
CN (2) CN101416949A (hu)
AR (1) AR029538A1 (hu)
AT (1) ATE453391T1 (hu)
AU (2) AU2001271741B2 (hu)
BR (1) BR0112242A (hu)
CA (1) CA2415058A1 (hu)
CY (1) CY1109915T1 (hu)
DE (1) DE60140945D1 (hu)
DK (1) DK1309327T3 (hu)
EA (1) EA006386B1 (hu)
ES (1) ES2336304T3 (hu)
HU (1) HUP0301422A3 (hu)
IL (2) IL153647A0 (hu)
MX (1) MXPA02012891A (hu)
NO (1) NO20030030L (hu)
NZ (1) NZ523330A (hu)
PL (1) PL204866B1 (hu)
PT (1) PT1309327E (hu)
SI (1) SI1309327T1 (hu)
TW (1) TWI294777B (hu)
WO (1) WO2002003987A2 (hu)
ZA (1) ZA200301004B (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030858A2 (en) * 2001-05-01 2005-08-31 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
AU2003248707A1 (en) * 2002-06-13 2003-12-31 Wyeth Bazedoxifene treatment regimens
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
SG149081A1 (en) * 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
PE20060676A1 (es) 2004-04-07 2006-07-24 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
EP1732889A1 (en) * 2004-04-07 2006-12-20 Wyeth Crystalline polymorph of bazedoxifene acetate
US7504394B2 (en) * 2004-04-08 2009-03-17 Wyeth Bazedoxifene ascorbate
UA86056C2 (ru) * 2004-04-08 2009-03-25 Уайет Твердый дисперсионный состав базедоксифена ацетата, способ его получения (варианты) и применение (варианты)
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN100358517C (zh) * 2004-09-28 2008-01-02 马晶 一种枸橼酸他莫昔芬口腔崩解片及其制备方法
EP1787642A1 (en) * 2004-11-10 2007-05-23 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
ATE365546T1 (de) * 2004-11-10 2007-07-15 Teva Pharma Verfahren zur herstellung von komprimierten festen dosierungsformen, das gut zur verwendung mit schlecht wasserlöslichen arzneistoffen geeignet ist, und danach hergestellte komprimierte feste dosierungsformen
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20060223791A1 (en) * 2005-03-31 2006-10-05 Wyeth O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
CN101252921A (zh) * 2005-06-29 2008-08-27 惠氏公司 轭合雌激素类物质和苯卓昔芬的制剂
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
AR056471A1 (es) * 2005-08-24 2007-10-10 Wyeth Corp Formulaciones de acetato de bazedoxifeno
TW200836774A (en) * 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
WO2009049643A1 (en) * 2007-10-16 2009-04-23 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
WO2009146097A1 (en) * 2008-04-02 2009-12-03 Dr. Reddy's Laboratories Ltd. Raloxifene pharmaceutical formulations
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
EP2448562B1 (en) 2009-07-02 2013-11-06 Synthon B.V. Raloxifene composition
EP2493477B1 (en) 2009-10-27 2013-10-16 Wyeth LLC Bazedoxifene formulations with antioxidants
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
KR102145641B1 (ko) 2012-06-05 2020-08-18 다케다 야쿠힌 고교 가부시키가이샤 고형 제제
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
MX373103B (es) 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
CA2980328A1 (en) 2015-04-02 2016-10-06 Theravance Biopharma R&D Ip, Llc Combination dosage form of a mu opioid receptor antagonist and an opioid agent
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
CN110402244B (zh) 2015-08-12 2023-02-03 因赛特公司 Lsd1抑制剂的盐
WO2018010543A1 (zh) * 2016-07-11 2018-01-18 武汉朗来科技发展有限公司 一种用于口服固体制剂的复合崩解剂体系及含有该复合崩解剂体系的口服固体制剂
KR101683193B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
KR101683192B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
CN107951034B (zh) * 2017-12-01 2021-03-23 郑州拓洋生物工程有限公司 维生素泡腾制剂及其制备方法
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
RU2732291C1 (ru) * 2020-02-13 2020-09-15 Открытое акционерное общество "Фармстандарт-Лексредства" (ОАО "Фармстандарт-Лексредства") Лекарственный препарат на основе травы алтея лекарственного для лечения простудных и острых респираторных заболеваний
CN115526105A (zh) * 2022-10-09 2022-12-27 北部湾大学 一种基于多元快速迭代滤波分解法的刀具磨损预测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3552727A (en) * 1968-09-18 1971-01-05 American Air Filter Co Gas scrubbing apparatus
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3029742B2 (ja) * 1992-08-20 2000-04-04 株式会社東芝 画像補正装置
JPH0674903A (ja) * 1992-08-26 1994-03-18 Sumitomo Metal Ind Ltd 平板状被検出材の微小欠陥検出方法及び装置
FR2698788B1 (fr) 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
US5342133A (en) * 1992-12-23 1994-08-30 Hewlett-Packard Company Paper moving system for a printer/plotter
US5332727A (en) 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5919800A (en) 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
EP0729956B1 (en) * 1995-02-28 2001-10-31 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
DE69707189T2 (de) * 1996-04-19 2002-06-20 American Home Products Corp., Madison Östrogene Verbindungen
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
HUP0004419A3 (en) 1997-10-15 2002-01-28 Wyeth Corp Novel aryloxy-alkyl-dialkylamines and process for producing them
JP2002521322A (ja) * 1998-07-23 2002-07-16 ノボ ノルディスク アクティーゼルスカブ 安定な医薬製剤の製造のための湿式顆粒化方法

Also Published As

Publication number Publication date
DE60140945D1 (de) 2010-02-11
KR100862174B1 (ko) 2008-10-09
US20080269198A1 (en) 2008-10-30
EA200300122A1 (ru) 2003-06-26
WO2002003987A3 (en) 2002-07-11
IL153647A (en) 2011-03-31
EP1309327B1 (en) 2009-12-30
WO2002003987A2 (en) 2002-01-17
ATE453391T1 (de) 2010-01-15
ES2336304T3 (es) 2010-04-12
CN1450895A (zh) 2003-10-22
AU2001271741B2 (en) 2006-10-19
CA2415058A1 (en) 2002-01-17
NO20030030L (no) 2003-03-03
EP1309327A2 (en) 2003-05-14
IL153647A0 (en) 2003-07-06
SI1309327T1 (sl) 2010-03-31
US20020031548A1 (en) 2002-03-14
CN101416949A (zh) 2009-04-29
HUP0301422A2 (hu) 2003-09-29
MXPA02012891A (es) 2003-10-24
NO20030030D0 (no) 2003-01-03
PL204866B1 (pl) 2010-02-26
KR20030023689A (ko) 2003-03-19
EA006386B1 (ru) 2005-12-29
KR100894027B1 (ko) 2009-04-22
DK1309327T3 (da) 2010-04-26
JP2004502733A (ja) 2004-01-29
TWI294777B (en) 2008-03-21
ZA200301004B (en) 2004-05-05
US7759386B2 (en) 2010-07-20
BR0112242A (pt) 2003-06-24
AU7174101A (en) 2002-01-21
CY1109915T1 (el) 2014-09-10
PT1309327E (pt) 2010-02-23
KR20070110454A (ko) 2007-11-16
PL365875A1 (en) 2005-01-10
NZ523330A (en) 2005-07-29
AR029538A1 (es) 2003-07-02

Similar Documents

Publication Publication Date Title
HUP0301422A3 (en) Pharmaceutical compositions of estrogenic agents
GB2358583B (en) Pharmaceutical compositions
HUP0300582A3 (en) Pharmaceutical compositions
IL162581A0 (en) Pharmaceutical compositions containing corticosteroids
AU6219601A (en) Pharmaceutical compositions
HUP0204137A3 (en) Pharmaceutical composition comprising fulvestrant
GB0009584D0 (en) Pharmaceutical compositions
HUP0203311A3 (en) New pharmaceutical compositions of prolonged effect
AU8576801A (en) Pharmaceutical compositions
HUP0400553A3 (en) Pharmaceutical compositions
AU1390002A (en) Pharmaceutical compositions
GB0008485D0 (en) Pharmaceutical compositions
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0301317A3 (en) Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
GB0009609D0 (en) Therapeutic compositions
PL357020A1 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
GB0030857D0 (en) Therapeutic compositions
HUP0301134A3 (en) Use of 7-hydroxyepiandrosterone having neuroprotective activity for preparing pharmaceutical compositions
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions
AU8254101A (en) Medicinal compositions
HK1052652A (en) Pharmaceutical compositions of estrogenic agents
GB0000916D0 (en) New compositions of matter
GB0000062D0 (en) Pharmaceutical compositions
GB0031288D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees